Neurogene Inc
NASDAQ:NGNE

Watchlist Manager
Neurogene Inc Logo
Neurogene Inc
NASDAQ:NGNE
Watchlist
Price: 17.96 USD 2.51%
Market Cap: 278.2m USD

Neurogene Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neurogene Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Neurogene Inc
NASDAQ:NGNE
Stock-Based Compensation
$13.3m
CAGR 3-Years
N/A
CAGR 5-Years
31%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$962m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
$886m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
$503m
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$696.1m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
$1B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
10%
No Stocks Found

Neurogene Inc
Glance View

Market Cap
278.2m USD
Industry
Biotechnology

Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.

NGNE Intrinsic Value
8.79 USD
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Neurogene Inc's Stock-Based Compensation?
Stock-Based Compensation
13.3m USD

Based on the financial report for Sep 30, 2025, Neurogene Inc's Stock-Based Compensation amounts to 13.3m USD.

What is Neurogene Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
31%

Over the last year, the Stock-Based Compensation growth was 88%.

Back to Top